82 | Robin Carhart-Harris on Psychedelics and the Brain
What this covers
Robin Carhart-Harris, director of the Centre for Psychedelic Research at Imperial College London, discusses the neuropharmacology of classic psychedelics and their emerging therapeutic potential. He and host Sean Carroll examine how drugs like psilocybin and LSD work in the brain—specifically by stimulating the serotonin 2A receptor to increase the unpredictability of neural activity—and why this mechanism appears useful across a range of psychiatric conditions. The conversation moves from the molecular and systems-level neuroscience through clinical evidence and into questions of policy, philosophy, and what constitutes safe, intelligent use of these substances.
The range of territory is broad. Carhart-Harris explains the pharmacology of different psychedelics, distinguishing between the short, entity-laden intensity of smoked DMT and the longer, therapeutically oriented arc of psilocybin and LSD. He frames psychedelic action through the Bayesian Brain hypothesis and the Entropic Brain principle—the idea that these drugs relax the brain's confidence in its internal models, including the sense of self, allowing people to escape the cognitive ruts that underlie depression, addiction, and other disorders. The conversation includes controlled trial data from Johns Hopkins and NYU on end-of-life anxiety, the role of set and setting and integration in shaping outcomes, and Carhart-Harris's skepticism toward pseudoscientific interpretations of psychedelic experience. A significant theme concerns policy and access: he argues for carefully managed medical centers over simple decriminalization, and questions the regulatory mismatch that keeps safer drugs like LSD prohibited while alcohol remains legal. The historical backdrop includes the 1971 UN ban that halted decades of research, and a brief sketch of how Albert Hoffman discovered LSD's effects by accident in 1943.
Carhart-Harris argues that classic psychedelics work by stimulating cortical serotonin 2A receptors to increase the entropy (unpredictability) of brain activity, which relaxes the precision of internal models like the sense of self, producing a trans-diagnostic therapeutic effect that can flatten the cognitive 'ruts' underlying depression, addiction, and other disorders when used in carefully managed contexts.
- Classic psychedelics share the pharmacological property of stimulating the serotonin 2A receptor, heavily expressed in the high-level association cortex.
- Psychedelics increase the entropy/unpredictability of spontaneous brain activity, relaxing confidence in internal models including the self.
- Because many disorders involve rigid cognitive/behavioral 'ruts', psychedelic therapy has a trans-diagnostic action rather than targeting one diagnosis.
Classic psychedelics work by disrupting the brain's rigid top-down models and increasing entropy of spontaneous activity.
- A well-functioning brain or mind is about balancing organization against freedom and randomness; sometimes increasing entropy is useful (a controlled increase) when that balance is too rigid, and this may be a universal principle of destruction breeding better new organization that extends beyond the brain.
“Controlled increase in entropy.”
- Under the Bayesian brain view, much of perception is constructed top-down from internal models we house rather than received from the outside world; psychedelics work by relaxing the precision/confidence weighting of these internal models (including the sense of self), allowing a person to almost observe the models from outside as they break down.
“so much of experience is the product, in a sense, of these models that we house, rather than some kind of receptivity of information coming in”
- The entropic brain principle holds that psychedelics increase the unpredictability (entropy) of spontaneous brain activity, producing richer ongoing consciousness; there is a reliable relationship between the richness of conscious content and the entropy of brain activity.
“the principle with psychedelics is quite simple, this entropic brain principle, which is that psychedelics increase the unpredictability of spontaneous brain activity”
- Serotonin is not a simple excitatory or inhibitory signal but a complex neuromodulator that tunes neural function, reflected in its at least 14 sub-receptors that do different things, some opposing each other; the 2A receptor specifically is excitatory and increases an irregular form of excitation.
“serotonin is a really complex neuro modulator, so it tunes neural function rather than it being a simple excitation or inhibition thing”
- The serotonin 2A receptor is heavily expressed in the cortex—evolutionarily recent and massively expanded in humans—and is especially concentrated in the association cortex at the top of the brain's hierarchy, which underlies high-level functions like imagination, counterfactual thinking, and self-consciousness.
“the receptor is heavily expressed in the cortex, that aspect of brain that humans have so much of, all the wrinkly stuff, and massively expanded in our species”
- The scientifically crisp definition of a classic psychedelic is pharmacological: LSD, psilocybin, DMT, and mescaline all share the property of stimulating the serotonin 2A receptor, which distinguishes them from loosely 'psychedelic' drugs like cannabis or MDMA.
“all of these classic psychedelics share a certain pharmacological property, which is that they stimulate a certain serotonin receptor, the serotonin 2A receptor”
Psychedelics treat diverse disorders sharing underlying cognitive ruts by enabling flexible exploration and breaking rigid patterns.
- The biggest block to creativity is being too sure or too confident; psychedelics promote creativity by relaxing that confidence (ego dissolution) and expanding the range of thought, whereas stimulants like cocaine inflate the ego and may produce productive but stereotyped, non-expansive output.
“Probably the biggest block to creativity is being too sure, being too confident.”
- Rather than acting as a 'magic bullet' for a single diagnosis, psychedelic therapy shows signal across many disorders (depression, treatment-resistant depression, anxiety, end-of-life distress, addictions, eating disorders, chronic pain, OCD) because these disorders share an underlying structure of cognitive and behavioral 'ruts'; psychedelics flatten the depressed/addicted landscape so the person can explore and move more freely.
“psychedelic therapy has what we call a trans-diagnostic action”
- Because blocking the 2A receptor has only subtle baseline effects, Carhart-Harris hypothesizes the serotonin 2A system functions as a 'crisis button' that becomes naturally engaged during exceptional conditions of existential distress, inducing hyper-plastic brain and mind states that enable transformative change—analogous to religious epiphanies or hitting rock bottom.
“maybe it becomes engaged naturally during exceptional conditions... it's a kind of crisis button, in a way, activating the 2A system”
- Paradoxically, although psychedelics are drugs, they appear useful for treating addictions to other substances (alcohol, tobacco) by helping people jump out of the cognitive and behavioral ruts that characterize addiction, which Matt Johnson frames as treating 'addiction broadly defined.'
“psychedelics seem to be useful in curing people that on... From being addicted to other drugs, is that right?”
Safe psychedelic use requires regulated medical centers with screening, integration care, and proper set-and-setting infrastructure.
- Carhart-Harris favors a roll-out through carefully and professionally managed centers—with screening for vulnerabilities, mental health professionals, careful music and environment, and after-care—rather than decriminalization, arguing the regulated medical-product route is a more thoughtful and healthier way for psychedelics to enter society.
“is decriminalization really the right way for this to roll out? I think initiatives that are thinking more carefully about the roll-out of psychedelic therapy... are much more thoughtful”
- The integration or 'landing' process after a psychedelic experience is critically important, and insights settle most healthily when allowed to crystallize organically without forced interpretation or premature closure; therapists have a responsibility not to force closure on uncertain questions (e.g., 'Was I abused?'), since forcing closure has gone wrong in traditional psychotherapy.
“the integration process, the landing process, after a big psychedelic experience is so important”
- Safe psychedelic use depends critically on context: not just the setting of the immediate experience but also prior intention and preparation and planned after-care ('the landing'); if these are covered, a rational case can be made for opening up access to safe psychedelic use within regulated centers.
“it's so important that it is, that the psychedelic be taken in the right kind of context”
- Conventional clinical trials that constrain a single indication into small, narrow studies for financial reasons are ill-suited to psychedelic therapy; instead, adaptive trials and basket trials—testing one intervention across a broad population and range of indications with adaptable dose, sessions, and integration care—borrowed from oncology, could better fit a trans-diagnostic, still-young science despite tension with the precision-medicine fashion.
“if you could set up a trial that perhaps looks at a range of different indications or a very broad population”
Psychedelics show clinical efficacy and safety across rigorous trials, with excellent toxicity profiles and no addiction potential.
- Well-designed double-blind randomized controlled trials at NYU and Johns Hopkins have shown rapid and enduring reductions in depressive and anxiety symptoms in end-of-life distress, with patients reporting feeling much more at ease with their inevitable passing and viewing death as less frightening.
“the results have been very compelling, so rapid and enduring improvements in the main mental health outcomes, which have been depressive and anxiety symptoms”
- Classic psychedelics like psilocybin have an excellent toxicity profile with a massive therapeutic index (large gap between an effective dose and a harmful one), negligible addiction potential (animals do not self-administer them and they are fundamentally aversive), and no physiological mortality risk—the main dangers being behavioral and psychological vulnerability.
“toxicity profile seems to be very good, especially with a compound like psilocybin, magic mushrooms, massive therapeutic index”
- After decades of research hiatus, pioneering work in the 1990s by figures like Rick Strassman and Franz Vollenweider brought psychedelic compounds back into the scientific space, followed by significant work at Johns Hopkins in the 2000s and brain-imaging research with psilocybin in the UK from around 2009.
“in the '90s, most significantly, you have characters like Rick Strassman and Franz Vollenweider doing pioneering work to bring psychedelic compounds back into the scientific space”
Psychedelics resemble dream states accessing the unconscious; spiritual experiences benefit from naturalistic scientific explanation rather than metaphysical claims.
- While psychedelics may give people insights about the nature of nature, the claim that they reveal the fundamental nature of external reality is treated skeptically; much advocacy slides into pseudoscience and self-contradictory magical thinking (e.g., vague vagus-nerve-kundalini claims) that is itself reductionist.
“there's a lot of pseudoscience that comes into this space, a lot of magical notions, and a lot of contradiction”
- A naturalistic, scientific demystification of what happens in the brain during profound spiritual psychedelic experiences would, paradoxically, be healthy for spiritual practice itself, and Carhart-Harris is confident the naturalistic approach will win out as it historically has, despite some resistance.
“there will be this healthy demystification, which is good, paradoxically, for spiritual practice, I would say”
- Some trips are genuinely awful (hellish), and the best scientific way to understand these experiences is by reference to Jungian notions of the collective unconscious and archetypes (demons, devils, monsters) rather than treating them as literally real metaphysical entities, which Carhart-Harris regards as a pitfall of psychedelic use.
“I would lean towards notions of the collective unconscious, Carl Jung and archetypes around demons and devils and monsters”
- The psychedelic state is likely a hybrid waking dream state in which part of the mechanics and physiology of dreaming occur while awake, supporting the idea—echoing Freud's 'royal road to the unconscious'—that both dreams and psychedelics provide converging access to the unconscious mind.
“the tripping state, if you want, is a hybrid waking dream state. So part of the mechanics and physiology of dreaming is actually happening while you're awake under a psychedelic”
Legal and regulatory barriers including expensive licensing and grant difficulty currently hamper psychedelic research progress.
- Conducting psychedelic research legally requires an expensive, non-trivial Home Office license with requirements like a wall-bolted locked fridge, building work, inspections, and listing—plus difficult grant funding—which collectively hamper science and collaboration and deter researchers from bothering.
“You get a license from the Home Office, and it's not trivial to get one and they're quite expensive, and that's a shame because it hampers science”
- A late-1960s political and social backlash—tied to counter-cultural movements, the Vietnam war, fear of anti-authoritarian sentiment, and politicians finding being 'tough on drugs' a vote-winner—led to a UN-wide ban that effectively halted psychedelic research and medical use for decades.
“it seems there was a fear that perhaps psychedelics were fueling some of the counter-cultural sentiments”
Three waves of psychedelic history span ancient plant use, twentieth-century LSD discovery, and current scientific renaissance.
- Psychedelic history unfolds in three waves: ancient plant-medicine use in Central and South America going back thousands of years, a second 20th-century wave beginning with the synthesis and discovery of LSD's effects, and the current 'Third Wave' renaissance of scientific and clinical research.
“You have the first wave of psychedelic plant medicine use, which is ancient, in major geographical areas in Central America and South America”
- LSD was synthesized by Albert Hoffman in 1938 while researching ergot derivatives for vascular effects (potentially to stem bleeding in birth), and its psychedelic effects were discovered only by accident in 1943 when he ingested what he wrongly thought was a tiny dose, marking the first 'Bicycle Day.'
“it was a classic medical serendipity that led him to...”
- Intravenous or smoked DMT produces a short (under 20 minutes) but extremely intense, visually rich, hyper-real experience in which people often report encountering seemingly sentient entities, contrasting with longer-lasting psychedelics like LSD and oral psilocybin that distort existing perception and yield more therapeutic, gradually emerging personal material.
“it rockets people into this DMT space where they feel so profoundly immersed in this other world that feels as real as this one”
- Beyond treating diagnosed disorders, intelligent psychedelic use within managed centers could become part of maintaining mental wellness for well people—improving resilience, perspective, and connectedness—especially when tied to other healthy practices like diet, meditation, and yoga, functioning as a kind of prophylaxis against the massive burden of mental illness.
“maybe people who are well, as well that could be benefit from, still the effect on their psychological well-being, how it might help keep them well”